LAURUSLABS

Laurus Labs, a prominent player in the Pharmaceuticals & Drugs industry This change is attributed to a shift in technical trends from bullish to mildly bullish. The current stock price stands at 586.00, down from a previous close of 610.25, with a 52-week high of 660.90 and a low of 386.85. In terms of valuation, Laurus Labs has transitioned from an expensive to a fair rating, with a PE ratio of 88.19 and a PEG ratio of 0.72. The company has demonstrated strong financial performance, reporting a remarkable 210.5% growth in net profit for Q4 FY24-25, alongside a high return on capital employed (ROCE) of 8.82%. Over the past year, Laurus Labs has outperformed the market, achieving a return of 34.98%, significantly higher than the BSE 500's 5.01%. With high institutional holdings at 37.29%, the company continues to showcase its robust operational efficiency and market resilience.